
Crizanlizumab
Form: IV Infusion
Strength: 100 mg/10 mL (10 mg/mL)
Reference Brands: Adakveo®(EU & US)
Category: Anemia
rizanlizumab (Adakveo®) is a breakthrough biologic therapy for sickle cell disease, available for B2B pharmaceutical distribution across the US and EU markets. It is a humanized monoclonal antibody (anti-P-selectin) used to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell anemia. Approved by the FDA and EMA, Crizanlizumab is supplied as a 100 mg/10 mL IV infusion, ideal for hospital and specialty clinic use. Pharma B2B partners benefit from secure supply chains, regulatory-compliant sourcing, and access to one of the most innovative therapies in hematology. Reliable distribution and market-ready packaging ensure smooth commercialization across regulated markets.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Deferoxamine
Strength: 500 mg/vial, 2 g/vial
Form: Lyophilized powder for injection
Reference Brands: Desferal
View Details Get EnquiryDeferasirox
Strength: 125 mg, 250 mg, 500 mg
Form: Tablets for Oral Suspension
Reference Brands: Exjade, Jadenu (film-coated)
View Details Get EnquiryIron(III)-Isomaltoside Injection
Strength: 100mg/ml
Form: Injection
Reference Brands: Monofer,, Diafer, Monoferric
View Details Get EnquiryIron Dextran
Strength: 50 mg/mL
Form: injection
Reference Brands: Dexferrum,INFeD
View Details Get Enquiry